Enzene Biosciences has launched a new Drug Discovery Division, which will expand the CDMOs breadth of services to the biotech industry.
The new division will further compleiment Enzene’s US biologics manufacturing site, which will open later this summer.
Addressing industry demands
Enzene’s new discovery arm will provide end-to-end integrated discovery services in response to the rapidly growing industry demands, according to the company.
Offerings will include antibody services (target validation, discovery and engineering); reagent production, ranging from custom peptides and proteins to advanced modalities like plasmids, RNA and exosomes; and multi-platforms assays services.
While financial details remain undisclosed, the new Discovery Division will be located at Enzene’s Pune facility, with new discovery laboratories set to be operational by July and further expansions planned later in the year.
By integrating its existing capabilities in bioprocessing, product development and commercialisation with the new discovery capabilities, the company aims to emerge as a fully integrated, one-stop solutions provider for companies working from development to commercialisation.
“There is a global shortage of biology services, and our clients are increasingly looking to collaborate with us much earlier in the discovery phase to expedite their progress to IND and beyond. We anticipate even greater demand for these services in the coming year as the resurgence in biotech funding leads to more targets entering discovery – with contract R&D empowering them to advance more targets simultaneously,” commented Himanshu Gadgil, CEO of Enzene Biosciences.
BIO 2024
The news comes at an opportune moment for many US based innovators who are using BIO 2024 to diversify partners.
This shift away from China is being accelerated by the ongoing Biosecure Act, with biotechs and pharma companies searching for new CRO discovery services and manufacturing partners for biologics (clinical and commercial).
Enzene will open its USD $50m New Jersey site this summer, which will also be the first site in the USA with a fully connected continuous manufacturing platform and will be staffed by more than 300 personnel.
The CDMO has immediately available capacity to produce complex proteins along with standard modalities via both CHO and mammalian cell lines.
